https://ymaho.com/asundexian-fda-priority-status-stroke-prevention-without-bleeding
The drug asundexian (Bayer) received FDA priority status for preventing recurrent stroke. Risk reduction of 26% without increased bleeding. Details of the OCEANIC-STROKE study.